Transforming Lives

Through a new class of safe, durable cancer treatments.

In The News

    • MAY 29 2019

    BioSpace: ASCO 2019 Preview: Presentations to Keep An Eye On

    Oncoceutics, Inc. – Philadelphia-based Oncoceutics, Inc. will showcase data from its ongoing trial assessing ONC201 in adult recurrent H3 K27M-mutant glioma. The oral abstract session presentation, entitled “Single agent ONC201 in adult recurrent H3 K27M-mutant glioma” will describe the clinical experience of ONC201, in adults with recurrent H3 K27M-mutant glioma. ONC201 is an orally active